Alexion Pharmaceuticals
By therapeutic area
| Therapeutic area | Premium | Deals |
|---|---|---|
| rareDisease | ×0.85 | 3 |
By stage at signing
Not enough phase-specific data (need ≥3 deals per phase).
Strategy profile
Based on 15 disclosed transactions, Alexion Pharmaceuticals concentrates its licensing activity in RareDisease, Metabolic, and Cardiovascular. Alexion Pharmaceuticals pays a 0.84x discount to market median, with the strongest premiums in RareDisease (0.85x). Their most common deal structure is Option, with an average disclosed value of $3.5B. Most recent activity: 2026.
Premium by therapeutic area
How Alexion Pharmaceuticals pays relative to peer medians in each TA
Pipeline coverage & gaps
Alexion Pharmaceuticals has disclosed activity in 1 of 12 tracked therapeutic areas. Gaps may represent whitespace opportunities for licensors.
Deal type breakdown
How this buyer structures its transactions
| Deal type | Count | Avg upfront | Avg total value |
|---|---|---|---|
| OptionPrimary | 5 | $25M | $1.7B |
| AcquisitionPrimary | 5 | $8.4B | $8.7B |
| License | 4 | $21M | $62M |
| Collaboration | 1 | $22M | $622M |
Recent disclosed deals
| Year | Asset | Licensor | Indication | Phase | Upfront | Total |
|---|---|---|---|---|---|---|
| 2026 | next-generation obesity and type 2 diabetes programs (eight programs) | CSPC Pharmaceutical Group | obesity and type 2 diabetes | preclinical | — | $4.7B |
| 2025 | AAV gene therapy programs (up to 5) | JCR Pharmaceuticals | — | preclinical | — | $825M |
| 2021 | — | Caelum Biosciences | AL Amyloidosis | phase_2 | $500M | $1.0B |
| 2020 | Alexion portfolio | AstraZeneca | PNH and aHUS | approved | $39.0B | $39.0B |
| 2020 | Andexanet alfa (Andexxa) | Portola Pharmaceuticals | Reversal of Factor Xa Inhibitors | approved | $1.4B | $1.4B |
| 2019 | Complement-pathway RNAi programs | Dicerna Pharmaceuticals, Inc. | rare_disease | preclinical | $20M | $620M |
| 2019 | Danicopan (Factor D inhibitor) | Achillion Pharmaceuticals | Paroxysmal Nocturnal Hemoglobinuria | phase_2 | $930M | $930M |
| 2019 | elamipretide | Stealth BioTherapeutics Corp | primary mitochondrial myopathy, Barth syndrome, Leber's hereditary optic neuropathy | phase_3 | $30M | $470M |
| 2019 | AG10 | Eidos Therapeutics, Inc. | transthyretin amyloidosis (ATTR) | phase_3 | $25M | $55M |
| 2019 | AG10 | Eidos Therapeutics | ATTR amyloidosis | phase_2 | $25M | $55M |
| 2019 | AG10 | BridgeBio Pharma, Inc. | ATTR cardiomyopathy | phase_2 | $25M | $55M |
| 2019 | complement-pathway targets | Zealand Pharma | complement-mediated diseases | discovery | $25M | $2.0B |
| 2018 | RNAi complement pathway targets | Dicerna Pharmaceuticals, Inc. | complement-mediated diseases | preclinical | $22M | $622M |
| 2018 | SYNT001 (anti-FcRn) | Syntimmune | Warm Autoimmune Hemolytic Anemia | phase_1 | $400M | $1.2B |
| 2017 | — | Arbutus Biopharma Corporation | rare_disease | preclinical | $8M | $83M |
How this is computed
For each Alexion Pharmaceuticals deal we find the median total deal value of comparable transactions (same therapeutic area + phase, falling back to TA-only with ≥3 peers). The buyer’s deal divided by the peer median is the per-deal premium. We trim outliers, take the trimmed mean, and clamp to [0.7×, 1.5×] to reject data errors. Confidence scales with sample size.
Trimmed mean of 3 disclosed deal premiums vs. peer medians. Raw premium 0.845, clamped to [0.7, 1.5].